TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
P/E ratio for TransMedics Group, Inc. (TMDX)
P/E ratio as of 2023: -102.55
According to TransMedics Group, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -102.55. At the end of 2022 the company had a P/E ratio of -50.35.
P/E ratio history for TransMedics Group, Inc. from 2016 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -102.55 |
| 2022 | -50.35 |
| 2021 | -11.97 |
| 2020 | -17.10 |
| 2019 | -7.87 |
| 2018 | -18.12 |
| 2017 | -15.55 |
| 2016 | -13.45 |